

GLAXOSMITHKLINE PLC

Form 6-K

August 10, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 10 August 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No ☒

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- | | |
|-------------------------------------|-------------------------|
| a) Name | Mrs V A Whyte |
| b) Position/status | SVP & Company Secretary |
| c) Initial notification / amendment | Initial Notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- | | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- | | |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
| b) Nature of the transaction | The receipt of 4,360 Ordinary Shares from spouse for nil consideration. |

- | | | |
|---------------------------|----------|-----------|
| | Price(s) | Volume(s) |
| c) Price(s) and volume(s) | £0.00 | 4,360 |

- | | |
|---------------------------|--------------------------|
| d) Aggregated information | n/a (single transaction) |
| Aggregated volume Price | |

- | | |
|----------------------------|------------|
| e) Date of the transaction | 2017-08-09 |
|----------------------------|------------|

- | | |
|-----------------------------|-----|
| f) Place of the transaction | n/a |
|-----------------------------|-----|

Details of PDMR/person closely associated with them ('PCA')

- | | |
|-------------------------------------|---|
| a) Name | Mr I W Whyte |
| b) Position/status | PCA of Mrs V A Whyte
(SVP & Company Secretary) |
| c) Initial notification / amendment | Initial Notification |
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- | | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- | | | | | | |
|--|--|----------|-----------|-------|-------|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | | | | |
| b) Nature of the transaction | Transfer of 4,360 Ordinary Shares to spouse for nil consideration. | | | | |
| c) Price(s) and volume(s) | <table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£0.00</td> <td>4,360</td> </tr> </table> | Price(s) | Volume(s) | £0.00 | 4,360 |
| Price(s) | Volume(s) | | | | |
| £0.00 | 4,360 | | | | |
| d) Aggregated information
Aggregated volume Price | n/a (single transaction) | | | | |
| e) Date of the transaction | 2017-08-09 | | | | |
| f) Place of the transaction | n/a | | | | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: August 10, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc